Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Slowdown Trips Up Lilly’s 2014 Revenue Estimates

This article was originally published in PharmAsia News

Executive Summary

Lilly says emerging markets represent “clear and significant opportunity” despite recent difficulties.

You may also be interested in...



Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands

MUMBAI - Explosive growth in India's anti-diabetes medicines market is turning arch rivals into allies. The latest example is of Eli Lilly & Co. combining forces with German giant Boehringer Ingelheim GmbH.

Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India

MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments

Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market

Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082873

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel